-
Je něco špatně v tomto záznamu ?
Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates
P. Pokorná, M. Šíma, B. Koch, D. Tibboel, O. Slanař
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, pozorovací studie
PubMed
34077940
DOI
10.1159/000515787
Knihovny.cz E-zdroje
- MeSH
- biologické modely * MeSH
- gestační stáří MeSH
- lidé MeSH
- monitorování léčiv metody MeSH
- novorozenec MeSH
- opioidní analgetika aplikace a dávkování farmakokinetika MeSH
- retrospektivní studie MeSH
- sufentanil aplikace a dávkování farmakokinetika MeSH
- tělesná hmotnost MeSH
- tkáňová distribuce MeSH
- umělé dýchání * MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
INTRODUCTION: Sufentanil is a potent synthetic opioid used for analgesia in neonates; however, data concerning drug disposition of sufentanil and dosage regimen are sparse in this population. Therefore, the aim of the study was to explore sufentanil disposition and to propose optimal loading and maintenance doses of sufentanil in ventilated full-term neonates. METHODS: Individual sufentanil pharmacokinetic parameters were calculated based on therapeutic drug monitoring data using a 2-compartmental model. Linear regression models were used to explore the covariates. RESULTS: The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively. Linear regression models showed relationship between Vdc (L) and GA (r2 = 0.3436; p = 0.0452) as well as BW (r2 = 0.4019; p = 0.0268). Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively. Median daily COMFORT-B (IQR) scores ranged from 6 to 23 while no significant relationship between pharmacokinetic parameters and COMFORT-B scores was found. DISCUSSION/CONCLUSION: Body weight and gestational age were found as weak covariates for sufentanil distribution, and the dosage regimen was developed for a prospective trial.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004743
- 003
- CZ-PrNML
- 005
- 20220127145027.0
- 007
- ta
- 008
- 220113s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000515787 $2 doi
- 035 __
- $a (PubMed)34077940
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pokorná, Pavla $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $u Intensive Care and Department of Paediatric Surgery, Erasmus MC, Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands
- 245 10
- $a Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates / $c P. Pokorná, M. Šíma, B. Koch, D. Tibboel, O. Slanař
- 520 9_
- $a INTRODUCTION: Sufentanil is a potent synthetic opioid used for analgesia in neonates; however, data concerning drug disposition of sufentanil and dosage regimen are sparse in this population. Therefore, the aim of the study was to explore sufentanil disposition and to propose optimal loading and maintenance doses of sufentanil in ventilated full-term neonates. METHODS: Individual sufentanil pharmacokinetic parameters were calculated based on therapeutic drug monitoring data using a 2-compartmental model. Linear regression models were used to explore the covariates. RESULTS: The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively. Linear regression models showed relationship between Vdc (L) and GA (r2 = 0.3436; p = 0.0452) as well as BW (r2 = 0.4019; p = 0.0268). Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively. Median daily COMFORT-B (IQR) scores ranged from 6 to 23 while no significant relationship between pharmacokinetic parameters and COMFORT-B scores was found. DISCUSSION/CONCLUSION: Body weight and gestational age were found as weak covariates for sufentanil distribution, and the dosage regimen was developed for a prospective trial.
- 650 _2
- $a opioidní analgetika $x aplikace a dávkování $x farmakokinetika $7 D000701
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a monitorování léčiv $x metody $7 D016903
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gestační stáří $7 D005865
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a biologické modely $7 D008954
- 650 12
- $a umělé dýchání $7 D012121
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a sufentanil $x aplikace a dávkování $x farmakokinetika $7 D017409
- 650 _2
- $a tkáňová distribuce $7 D014018
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
- 700 1_
- $a Koch, Birgit $u Department of Hospital Pharmacy, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Tibboel, Dick $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $u Intensive Care and Department of Paediatric Surgery, Erasmus MC, Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
- 773 0_
- $w MED00003791 $t Pharmacology $x 1423-0313 $g Roč. 106, č. 7-8 (2021), s. 384-389
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34077940 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145023 $b ABA008
- 999 __
- $a ok $b bmc $g 1752044 $s 1155892
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 106 $c 7-8 $d 384-389 $e 20210602 $i 1423-0313 $m Pharmacology $n Pharmacology $x MED00003791
- LZP __
- $a Pubmed-20220113